전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved23 programs
AntibodyLimited DatastaleChanghai HospitalPhase 2

TURBT (Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor, Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT))

Bladder Cancer · Bladder Cancer

#BladderCancer#Antibody#Phase2#monoclonal-antibody#Changhai
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#monoclonal-antibody#Triple-negativeBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#monoclonal-antibody#MetastaticGallbladderCarcinoma+1
Trials 1Status Recruiting

2 / 2 pages

← PreviousNext →